表紙
市場調查報告書

人副流感病毒3型感染疾病:開發中產品分析

Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018

出版商 Global Markets Direct 商品編碼 619904
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
人副流感病毒3型感染疾病:開發中產品分析 Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018
出版日期: 2018年09月28日內容資訊: 英文 33 Pages
簡介

人副流感病毒3型感染疾病,是引起嬰幼兒呼吸器官疾病,威脅生命的感染疾病。主要的症狀,包含發熱和咳嗽,鼻涕,假膜性喉炎,細支氣管炎,喘鳴,喉嚨頭痛等。主要的治療藥,有鎮痛、解熱用的成藥 (OTC) 等。

本報告提供全球各國的人副流感病毒3型感染疾病的治療藥的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業的簡介,主要藥物概要,最新的產業趨勢 (臨床實驗調查中斷中/已中止的產品等) 等。

目錄

  • 簡介
    • 分析範圍
  • 口腔乾燥症概要
  • 人副流感病毒3型感染疾病:治療藥的開發
    • 開發平台概要
    • 各企業的開發平台趨勢
    • 各大學、研究機關的開發平台趨勢
    • 企業開發中的產品
    • 在大學、研究機關開發中的產品
  • 人副流感病毒3型感染疾病:治療藥的評估
    • 各標的
    • 各作用機制
    • 各給藥途徑
    • 各分子類型
  • 人副流感病毒3型感染疾病:開發治療藥的企業
    • 3-V Biosciences Inc
    • Amarillo Biosciences Inc
    • Moderna Therapeutics Inc
  • 人副流感病毒3型感染疾病:藥物的簡介
    • 干擾素α
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • mRNA-1653
    • Paradase
    • 人副流感病毒第一型、3型感染疾病,血凝素、神經胺糖酸酶抑制用小分子
    • TVB-3567
  • 人副流感病毒3型感染疾病:暫停的計劃
  • 人副流感病毒3型感染疾病:開發中止的產品
  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10842IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.

Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.  

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Parainfluenza Virus 3 Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Parainfluenza Virus 3 Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Human Parainfluenza Virus 3 Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Human Parainfluenza Virus 3 Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Human Parainfluenza Virus 3 Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Human Parainfluenza Virus 3 Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Parainfluenza Virus 3 Infections - Overview
    • Human Parainfluenza Virus 3 Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Human Parainfluenza Virus 3 Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Human Parainfluenza Virus 3 Infections - Companies Involved in Therapeutics Development
    • 3-V Biosciences Inc
    • Amarillo Biosciences Inc
    • Moderna Therapeutics Inc
  • Human Parainfluenza Virus 3 Infections - Drug Profiles
    • interferon alpha - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mRNA-1653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Paradase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Hemagglutinin and Neuraminidase for Human Parainfluenza Virus 1 and 3 Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TVB-3567 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Human Parainfluenza Virus 3 Infections - Dormant Projects
  • Human Parainfluenza Virus 3 Infections - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Human Parainfluenza Virus 3 Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by 3-V Biosciences Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by Amarillo Biosciences Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Pipeline by Moderna Therapeutics Inc, H2 2018
  • Human Parainfluenza Virus 3 Infections - Dormant Projects, H2 2018
  • Human Parainfluenza Virus 3 Infections - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Human Parainfluenza Virus 3 Infections, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top